Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
INDIANAPOLIS, May 21, 2019 /PRNewswire/ -- In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 21, 2019 Category: Pharmaceuticals Source Type: clinical trials
VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)
Condition: Stress Interventions: Behavioral: R-CBSM; Biological: Influenza vaccine Sponsors: University of Miami; Florida Department of Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 20, 2019 Category: Research Source Type: clinical trials
